z-logo
open-access-imgOpen Access
Validated Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry Method for the Determination of Pramipexole in Human Plasma
Author(s) -
Manish Yadav,
R. Nageswara Rao,
Hemal Kurani,
J.R. Rathod,
Rashmin B. Patel,
Puran Singhal,
Pranav S. Shrivastav
Publication year - 2010
Publication title -
journal of chromatographic science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.362
H-Index - 56
eISSN - 1945-239X
pISSN - 0021-9665
DOI - 10.1093/chromsci/48.10.811
Subject(s) - chemistry , chromatography , selected reaction monitoring , triple quadrupole mass spectrometer , pramipexole , mass spectrometry , liquid chromatography–mass spectrometry , tandem mass spectrometry , high performance liquid chromatography , ammonium formate , quadrupole mass analyzer , analytical chemistry (journal) , medicine , disease , pathology , parkinson's disease
A sensitive and high throughput ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS-MS) method has been developed for the determination of pramipexole, a dopamine agonist, in human plasma. Sample preparation involved liquid-liquid extraction of pramipexole and ranitidine as the internal standard (IS) in ethyl acetate from 100 μL human plasma. The chromatographic separation is achieved on a Waters Acquity UPLC BEH C18 (100 mm × 2.1 mm, 1.7 μm) analytical column using an isocratic mobile phase, consisting of 10 mM ammonium formate (pH 7.50)-acetonitrile (15:85, v/v), at a flow-rate of 0.5 mL/min. The precursor → product ion transition for pramipexole (m/z 212.1 → 153.0) and IS (m/z 315.0 → 176.1) were monitored on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) and positive ion mode. The method was validated over a wide dynamic concentration range of 20-4020 pg/mL. Matrix effect is assessed by post-column infusion experiment and the process efficiency were 91.9% and 85.7% for pramipexole and IS, respectively. The method is rugged and rapid with a total run time of 1.5 min and is applied to a bioequivalence study of 0.25 mg PPX tablet formulation in 30 healthy Indian male subjects under fasting condition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom